Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 6Burkitt Lymphoma 6Neoplasm, Residual 3Leukemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1

Interventions

ibrutinib 2Bortezomib 2ponatinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1blinatumomab 1Rituximab 1Lenalidomide 1KW-2478 1Hsp90 inhibitor KU757 1Cyclophosphamide 1CA-4948 1Bendamustine Hydrochloride 1ARQ531 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoproliferative Disorders × blinatumomab × Clear all
NCT01471782 2017-02-08

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Amgen Research (Munich) GmbH

Phase 1/2 Completed
93 enrolled 21 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡